REN and metabolic dysfunction-associated steatohepatitis: Further support for the potential anti-fibrotic effect of drugs blocking renin-angiotensin system (RAS) comes from a cross sectional study of 290 hypertensive patients with NASH, which found that patients treated with ACEI or ARBs had less advanced fibrosis than patients treated with other anti-hypertensives [37].